Tags: Drug.
Omalizumab (trade name Xolair Roche/Genentech and Novartis) is a humanized antibody originally designed to reduce sensitivity to inhaled or ingested allergens especially in the control of moderate to severe allergic asthma which does not respond to high doses of corticosteroids. It has been approved for treating adult and adolescent patients 12 years and older with severe or moderate to severe allergic asthma in more than 90 countries since its first of such approval in 2002 in Australia.